Eesti - eesti - Ravimiamet

inresa arzneimittel gmbh - ketamiin - süstelahus - 50mg 1ml 10ml 5tk

Eesti - eesti - Ravimiamet

siegfried hameln gmbh - ketamiin - süstelahus - 50mg 1ml 10ml 10tk

Eesti - eesti - Ravimiamet

vetoquinol biowet sp. z o.o. - ketamiin - süstelahus - 100mg 1ml 50ml 1tk; 100mg 1ml 10ml 1tk

Eesti - eesti - Ravimiamet

spofa a.s - ketamiin - süstelahus - 50mg 1ml 50ml 1tk

Eesti - eesti - Ravimiamet

tov kharkivske farmatsevtychne pidpryemstvo zdorovya narodu - ketamiin - süstelahus - 50mg 1ml 2ml 10tk

Eesti - eesti - Ravimiamet

bela-pharm gmbh & co. kg - ketamiin - süstelahus - 100mg 1ml 10ml 1tk; 100mg 1ml 10ml 10tk; 100mg 1ml 25ml 1tk

Eesti - eesti - Ravimiamet

alfasan nederland b.v. - ketamiin - süstelahus - 100mg 1ml 10ml 5tk; 100mg 1ml 20ml 1tk; 100mg 1ml 50ml 1tk; 100mg 1ml 50ml 5tk; 100mg 1ml 20ml 5tk; 100mg 1ml 10ml 1tk; 100mg 1ml 50ml 15tk; 100mg 1ml 20ml 28tk

Eesti - eesti - Ravimiamet

panpharma laboratories - ketamiin - süstelahus - 50mg 1ml 10ml 25tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

ucb pharma s.a.   - fenfluramine hydrochloride - epilepsies, myoclonic - antiepileptics, - treatment of seizures associated with dravet syndrome as an add-on therapy to other antiepileptic medicines for patients 2 years of age and older. fintepla is indicated for the treatment of seizures associated with dravet syndrome and lennox-gastaut syndrome as an add-on therapy to other anti-epileptic medicines for patients 2 years of age and older.

Euroopa Liit - eesti - EMA (European Medicines Agency)

adienne s.r.l. s.u. - melphalan hydrochloride - multiple myeloma; hodgkin disease; lymphoma, non-hodgkin; precursor cell lymphoblastic leukemia-lymphoma; leukemia, myeloid, acute; neuroblastoma; ovarian neoplasms; hematopoietic stem cell transplantation - antineoplastilised ained - high-dose of phelinun used alone or in combination with other cytotoxic medicinal products and/or total body irradiation is indicated in the treatment of:multiple myeloma,malignant lymphoma (hodgkin, non-hodgkin lymphoma),acute lymphoblastic and myeloblastic leukemia,childhood neuroblastoma,ovarian cancer,mammary adenocarcinoma. phelinun in combination with other cytotoxic medicinal products is indicated as reduced intensity conditioning (ric) treatment prior to allogeneic haematopoietic stem cell transplantation (allo-hsct) in malignant haematological diseases in adults. phelinun in combination with other cytotoxic medicinal products is indicated as conditioning regimen prior to allogeneic haematopoietic stem cell transplantation in haematological diseases in the paediatric population as:myeloablative conditioning (mac) treatment in case of malignant haematological diseasesric treatment in case of non-malignant haematological diseases.